Fig. 4
From: Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit
Modulation of MHC-II-positive cells on trastuzumab treatment in HER2+ murine models. a, b Representative dot plots of MHC-II-positive cells in MI6 (a) and WTHER2 (b) tumours and frequency of MHC-II-positive cells in mice treated or not (NT) with trastuzumab by flow cytometry. p-values by unpaired t-test
